Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection

Journal of Viral Hepatitis

Volumn 11, Issue 3, 2004, Pages 271-276

  Suzuki, F ^a   Arase, Y ^a   Suzuki, Y ^a   Tsubota, A ^a   Akuta, N ^a   Hosaka, T ^a   Someya, T ^a   Kobayashi, M ^a,a   Saitoh, S ^a   Ikeda, K ^a   Matsuda, M ^a   Takagi, K ^a   Satoh, J ^a   Kumada, H ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Interferon therapy; MxA promoter gene; Single nucleotide polymorphism

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIVIRAL AGENTS; FEMALE; GENE FREQUENCY; GTP-BINDING PROTEINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 2442669165     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00509.x     Document Type: Article

References (26)

1. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321: 1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506-1510.
3. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
4. Pavlovic J, Zürcher T, Haller O, Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990; 64: 3370-3375.
5. Zhao H, De BP, Das T, Banerjee AK. Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Virology 1996; 220: 330-338.
6. Jakschies D, Zachoval R, Muller R et al. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatology 1994; 19: 857-865.
7. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O. MxA gene expression after liver virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994; 169: 807-813.
8. Fernández M, Antonio J, Quiroga JA et al. In vivo and In vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999; 180: 262-267.
9. Antonelli G, Simeoni E, Turriziani O et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy. J Interferon Cytokine Res 1999; 19: 243-251.
10. Matsushita M, Hijikata M, Matsushita M, Ohta Y, Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998; 29: 695-700.
11. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124-127.
12. Desmet VJ, Gerber M, Hoofnagel JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
13. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
14. Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000; 31: 819-827.
15. Chang KC, Hansen E, Foroni L, Lida J, Goldspink G. Molecular and functional analysis of the virus- and interferon-inducible human MxA promoter. Arch Virol 1991; 117: 1-15.
16. Nakade K, Honda H, Nagata K. Promoter structure of the MxA gene that confers resistance to influenza virus. FEBS Lett 1997; 418: 315-318.
17. Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analysing two SNP sites (-123 and - 88) in vivo and in vitro. Intervirology 2001; 44: 379-382.
18. King JK, Yeh SH, Lin MW et al. Genetic polymorphism in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002; 36: 1416-1424.
19. Sugimoto Y, Kuzushita N, Takehara T et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 377-384.
20. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequence encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990; 348: 741-744.
21. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N. Proteasomes and antigen processing. Adv Immunol 1997; 64: 1-38.
22. Yee LJ, Tang J, Gibson AW, Kimberly R, Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708-712.
23. Vidigal PG, Germer JJ, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-α, and transforming growth factor-β1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-277.
24. Rosen HR, McHutchison JG, Conrad AJ et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714-720.
25. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
26. Zeuzem S, Feinman SV, Rasensch J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.